---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-028383"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-04-10T23:59:59+00:00"
generated_at: "2026-06-17T04:15:05.375308+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics amends reverse stock split ratio range to 1-for-2 to 1-for-20

## Summary
- Amendment No. 1 changes the reverse stock split ratio range from 1-for-10–1-for-20 to 1-for-2–1-for-20.
- The amendment modifies Section 4.16(iii) of the Securities Purchase Agreement dated March 3, 2023.
- Company will seek stockholder approval of the revised reverse split range at the upcoming annual meeting.

## SEC filing metadata
- accession: 0001213900-23-028383
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023028383/0001213900-23-028383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023028383/ea176728-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-028383
- JSON: https://secwatch.observer/filing/0001213900-23-028383.json
- Plain text: https://secwatch.observer/filing/0001213900-23-028383.txt

## Key facts
- Material Agreements
  Unicycive Therapeutics, Inc. amended Amendment No. 1 with the investors named therein (effective 2023-04-06).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: the investors named therein
  - Effective: 2023-04-06
  source text: On April 6, 2023, Unicycive Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 to the Securities Purchase Agreement originally dated as of March 3, 2023 (‘Amendment No. 1”) pursuant to which the Company and the investors named therein agreed that, with respect to the upcoming annual meeting of stockholders, the Company would be seeking stockholder approval of a reverse stock split of its common stock at a specific ratio within a range of 1-for-2 to 1-for-20 rather than 1-for-10 to 1-for-20.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023028383/0001213900-23-028383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.